INS and type 1 diabetes mellitus: Nevertheless, retrospective data suggest a potential benefit in specific T1DM subsets (e.g., those with obesity and preserved self-insulin secretion), such as SPIDDM, but robust trials are still needed to establish safety and efficacy [6].